Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 05/06/24
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 04/18/24
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?Zacks Investment Research • 03/21/24
Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/20/24
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSPRNewsWire • 02/20/24
Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 02/14/24
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating ResultsPRNewsWire • 02/08/24
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PRNewsWire • 01/29/24
Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive?Zacks Investment Research • 01/24/24
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia GravisPRNewsWire • 01/18/24
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?Zacks Investment Research • 01/17/24
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PRNewsWire • 01/16/24
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer TypesPRNewsWire • 01/16/24